Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer
Author:
Publisher
Elsevier BV
Subject
General Pharmacology, Toxicology and Pharmaceutics
Reference42 articles.
1. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease;Bianchini;Nat Rev Clin Oncol,2016
2. Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer;Merino;Nat Commun,2019
3. Triple-negative breast cancer molecular subtyping and treatment progress;Yin;Breast Cancer Res,2020
4. The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial;Shigematsu;Clin Breast Cancer,2015
5. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting cytokine and chemokine signaling pathways for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-22
2. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy;Journal of Nanobiotechnology;2024-06-08
3. Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer;ACS Biomaterials Science & Engineering;2024-05-30
4. Recent trends in the delivery of RNA drugs: Beyond the liver, more than vaccine;European Journal of Pharmaceutics and Biopharmaceutics;2024-04
5. Metformin-Mediated Fast Charge-Reversal Nanohybrid for Deep Penetration Piezocatalysis-Augmented Chemodynamic Immunotherapy of Cancer;ACS Nano;2024-02-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3